U.S. Markets
UK's MHRA authorises orforglipron (LLY), making the UK the first Country in Europe to approve this glp-1 tablet for weight management and type 2 Diabetes
StockNow breaking-news AI analysis
UK MHRA authorized Eli Lilly's orforglipron as Europe's first GLP-1 tablet for weight and diabetes, following clinical data showing superior efficacy over oral semaglutide and enhanced patient convenience.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
